Tim-4 expressing monocytes as a novel indicator to assess disease activity and severity of ulcerative colitis

Life Sciences ◽  
2021 ◽  
Vol 269 ◽  
pp. 119077
Author(s):  
Guohui Xue ◽  
Lin Hua ◽  
Dongsheng Liu ◽  
Meijun Zhong ◽  
Yuanwang Chen ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity

P113 STUDY OF THE PROTEOMIC PROFILE IN PATIENTS WITH ULCERATIVE COLITIS, ITS CORRELATION WITH DIAGNOSIS AND DISEASE ACTIVITY

2018 ◽  
Vol 154 (1) ◽  
pp. S58
Author(s):  
Salah Badr El-Din ◽  
Ezzat Ali ◽  
Doaa Header ◽  
Pacint Moez ◽  
Mohamed Ibrahim
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Proteomic Profile

Disease activity, pANCA and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis

2009 ◽  
Vol 47 (09) ◽  
Author(s):  
M Jürgens ◽  
R Laubender ◽  
F Hartl ◽  
M Weidinger ◽  
J Wagner ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Early Response

scholarly journals Fecal microbiota dynamics during disease activity and remission in newly diagnosed and established ulcerative colitis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Lena Öhman ◽  
Anders Lasson ◽  
Anna Strömbeck ◽  
Stefan Isaksson ◽  
Marcus Hesselmar ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Gut Microbiota ◽  
Disease Activity ◽  
Temporal Dynamics ◽  
Fecal Microbiota ◽  
Disease Stage ◽  
Dietary Interventions ◽  
Microbial Composition ◽  
Fecal Samples ◽  
Specific Species

AbstractPatients with ulcerative colitis (UC) have an altered gut microbiota composition, but the microbial relationship to disease activity needs to be further elucidated. Therefore, temporal dynamics of the fecal microbial community during remission and flare was determined. Fecal samples were collected at 2–6 time-points from UC patients during established disease (cohort EST) and at diagnosis (cohort NEW). Sampling range for cohort EST was 3–10 months and for cohort NEW 36 months. Relapses were monitored for an additional three years for cohort EST. Microbial composition was assessed by Genetic Analysis GA-map Dysbiosis Test, targeting ≥ 300 bacteria. Eighteen patients in cohort EST (8 with maintained remission and 10 experiencing a flare), provided 71 fecal samples. In cohort NEW, 13 patients provided 49 fecal samples. The microbial composition showed no clustering related to disease activity in any cohort. Microbial dissimilarity was higher between than within patients for both cohorts, irrespective of presence of a flare. Microbial stability within patients was constant over time with no major shift in overall composition nor modification in the abundance of any specific species. Microbial composition was not affected by intensified medical treatment or linked to future disease course. Thus in UC, the gut microbiota is highly stable irrespective of disease stage, disease activity or treatment escalation. This suggests that prolonged dietary interventions or repeated fecal transplantations are needed to be able to induce permanent alterations of the gut microbiota.

scholarly journals Review article: the histological assessment of disease activity in ulcerative colitis

2015 ◽  
Vol 42 (8) ◽  
pp. 957-967 ◽  
Author(s):  
A. Marchal Bressenot ◽  
R. H. Riddell ◽  
C. Boulagnon-Rombi ◽  
W. Reinisch ◽  
S. Danese ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Review Article ◽  
Histological Assessment ◽  
Assessment Of Disease Activity

scholarly journals Efficacy of 5-Aminosalicylic Acid Enemas in the Treatment of Distal Ulcerative Colitis

1990 ◽  
Vol 4 (7) ◽  
pp. 468-471 ◽  
Author(s):  
MG Robinson ◽  
DL Decktor
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Activity Index ◽  
Disease Activity Index ◽  
First Episode ◽  
High Dose ◽  
Aminosalicylic Acid ◽  
Open Label ◽  
Distal Ulcerative Colitis ◽  
The Mean

The efficacy of 4 g 5-aminosalicylic acid (5-ASA, mesalamine) enemas was assessed in 666 patients with distal ulcerative colitis. Patients were enrolled in an open-label compassionate use program. One 4 g 5-ASA enema was administered each night for a period of four weeks and the disease activity index was assessed at baseline and on days 14 and 28. On days 14 and 28, 78.0% and 88.1% of patients, respectively, demonstrated an improvement in disease activity index. The mean decline in disease activity index on day 14 was 40.7% (P=0.0001) and on day 28 it was 55.4% (P=0.0001). Efficacy was similar whether the disease was confined to or extended beyond 30 cm from the anus. There was no difference in efficacy in patients suffering their first episode of disease compared to patients suffering subsequent attacks. In conclusion, high dose 5-ASA enemas are a highly effective treatment for distal ulcerative colitis.

Sign in / Sign up

Export Citation Format

Share Document